General Information of Drug Transporter (DT)
DT ID DTD0493 Transporter Info
Gene Name SLC9A8
Transporter Name Sodium/hydrogen exchanger 8
Gene ID
23315
UniProt ID
Q9Y2E8
Post-Translational Modification of This DT
Overview of SLC9A8 Modification Sites with Functional and Structural Information
Sequence
PTM type
X-Phosphorylation X: Amino Acid

Phosphorylation

  Serine

          3 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC9A8 [1] , [2]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

507

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC9A8 Serine 507 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC9A8 [3] , [4]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

571

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC9A8 Serine 571 has the potential to affect its expression or activity.

  PTM Phenomenon 3

Have the potential to influence SLC9A8 [3] , [4]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

573

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC9A8 Serine 573 has the potential to affect its expression or activity.

  Threonine

          4 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC9A8 [5]

Role of PTM

Potential impacts

Modified Residue

Threonine

Modified Location

467

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC9A8 Threonine 467 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC9A8 [2] , [6]

Role of PTM

Potential impacts

Modified Residue

Threonine

Modified Location

500

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC9A8 Threonine 500 has the potential to affect its expression or activity.

  PTM Phenomenon 3

Have the potential to influence SLC9A8 [1] , [2]

Role of PTM

Potential impacts

Modified Residue

Threonine

Modified Location

510

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC9A8 Threonine 510 has the potential to affect its expression or activity.

  PTM Phenomenon 4

Have the potential to influence SLC9A8 [7] , [8]

Role of PTM

Potential impacts

Modified Residue

Threonine

Modified Location

544

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC9A8 Threonine 544 has the potential to affect its expression or activity.

  Tyrosine

          3 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC9A8 [2] , [9]

Role of PTM

Potential impacts

Modified Residue

Tyrosine

Modified Location

514

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC9A8 Tyrosine 514 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC9A8 [2] , [9]

Role of PTM

Potential impacts

Modified Residue

Tyrosine

Modified Location

518

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC9A8 Tyrosine 518 has the potential to affect its expression or activity.

  PTM Phenomenon 3

Have the potential to influence SLC9A8 [9] , [10]

Role of PTM

Potential impacts

Modified Residue

Tyrosine

Modified Location

563

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC9A8 Tyrosine 563 has the potential to affect its expression or activity.
References
1 Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nat Commun. 2017 Mar 28;8:14864.
2 Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016 Jun 2;534(7605):55-62.
3 UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515.
4 A Methodological Assessment and Characterization of Genetically-Driven Variation in Three Human Phosphoproteomes. Sci Rep. 2018 Aug 14;8(1):12106.
5 iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics. 2012 Jun;11(6):M111.014423.
6 Identification of Missing Proteins in the Phosphoproteome of Kidney Cancer. J Proteome Res. 2017 Dec 1;16(12):4364-4373.
7 An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics. 2014 Jan 16;96:253-62.
8 Combination of multistep IMAC enrichment with high-pH reverse phase separation for in-depth phosphoproteomic profiling. J Proteome Res. 2013 Sep 6;12(9):4176-86.
9 Sensitive, Robust, and Cost-Effective Approach for Tyrosine Phosphoproteome Analysis. Anal Chem. 2017 Sep 5;89(17):9307-9314.
10 Finding the same needles in the haystack? A comparison of phosphotyrosine peptides enriched by immuno-affinity precipitation and metal-based affinity chromatography. J Proteomics. 2013 Oct 8;91:331-7.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.